full_text_results,p_value,ci,test_performed,effect_estimate_with_ci,endpoint_criterion_met,endpoint_id
"The combination of tislelizumab and TP regimen did not increase the incidence of adverse events, and no treatment-related adverse events for grade 3/4 were observed.",,,,,True,293
"At the data cutoff on 01/22/2025, the ORR (CR+PR) was 75%.",,,,,True,168
"median PFS was 3.4 months (95% confidence interval: 2.0, 4.4) with Nira (n=30) and 5.6 (3.7, 16.8) months with Nira+Cet (n=30, p=0.01)",0.01,,,,True,148
"median overall survival was 10.2 (6.4, 19.6) with Nira and 24.3 (9.5, not reached) months with Nira+Cet (p=0.01)",0.01,,,,True,147
"3y EFS was 30% (CI 20% – 40%) in arm A and 14% (CI 5% – 23%) in arm B with HR 0.66 (CI 0.49-0.89, p=0.005).",0.005,0.49-0.89,stratified logrank test,HR 0.66 (CI 0.49-0.89),True,325
"The ORR by ICR was 45.2% (14/31; 95% CI, 27.3–64.0), meeting the primary endpoint.",,"95% CI, 27.3–64.0",,"45.2% (95% CI, 27.3–64.0)",True,176
One DLT (grade 3 lethargy/fatigue) was observed at the MTD (2.5 x 10^7 cells).,,,,,True,16
One DLT (grade 3 lethargy/fatigue) was observed at the MTD (2.5 x 10^7 cells).,,,,,True,15
"As of 12/2024 and based on 25 evaluable pts, CRR at 3 mo was 68% (17/25).",,,,68% (17/25),True,142
"HHV-8 DNA declined at C4 (208 vs 41 copies/ml, p = 0.035)",0.035,,,,True,264
no HIV-VL... changes,,,,,True,265
no... CD4 changes,,,,,True,263
increased T-regs (p = 0.035),0.035,,,,True,267
decreased macrophages (p = 0.048) at C4,0.048,,,,True,268
"A non-significant rise was seen in NK, CD4, and CD8 naïve cells.",,,,,False,266
"16/22 (73%, one-sided 95% CI =53%-100%, p<.0001) had a MPR, of which 6 had a pathologic complete response (pCR), thus meeting the study's primary endpoint of 10 MPR.",0.0001,one-sided 95% CI =53%-100%,Simon Two-stage design,"73%, one-sided 95% CI =53%-100%",True,192
"Induction toripalimab plus chemotherapy exhibited significantly longer PFS compared to chemotherapy alone (median not reached [NR] vs NR; hazard ratio 0.25 [95% CI, 0.07-0.90], P=0.034).",0.034,"95% CI, 0.07-0.90",,"hazard ratio 0.25 [95% CI, 0.07-0.90]",True,229
"Three-months landmark analyses showed that patients with irAE have significantly longer OS than those without (29.3 vs. 22.1 months, P = 0.018).",0.018,,,,True,21
"Exploratory analyses demonstrated that patients with PDL1 CPS ≥10 had significantly longer PFS (13.7 vs 11.4 months, P = 0.039).",0.039,,,,True,22
"Patients with high TILs had significantly longer OS (23.1 vs.10.3 months, P = 0.003).",0.003,,,,True,20
"the activation of DNA repair pathway (HR,11.6, 95%CI 2.4-55.7, P = 0.002) was significantly associated with shorter PFS",0.002,95%CI 2.4-55.7,,"HR,11.6, 95%CI 2.4-55.7",True,17
"MYC target pathway (HR,7.4,95%CI 1.9-28.2, P = 0.004) was significantly associated with shorter PFS",0.004,95%CI 1.9-28.2,,"HR,7.4,95%CI 1.9-28.2",True,19
"the activation of KRAS signaling (HR,3.2, 95%CI 1.1-9.7, P = 0.035) was significantly associated with worse OS",0.035,95%CI 1.1-9.7,,"HR,3.2, 95%CI 1.1-9.7",True,18
"In SOFT, a moderate DFS benefit of T+OFS vs T (HR 0.85; 0.72-1.00) persisted",,0.72-1.00,,HR 0.85; 0.72-1.00,False,154
BCFI benefit was HR 0.82 (0.69-0.98),,0.69-0.98,,HR 0.82 (0.69-0.98),True,157
E+OFS vs T further reduced DFS events (HR 0.73; 0.61-0.86). The 15y DFS in SOFT was... 73.5% for E+OFS.,,0.61-0.86,,HR 0.73; 0.61-0.86,True,152
There were consistent but non-significant decreased hazards of death for T+OFS vs T (HR 0.87; 0.68-1.10).,,0.68-1.10,,HR 0.87; 0.68-1.10,False,160
There were consistent but non-significant decreased hazards of death for... E+OFS vs T (HR 0.85; 0.67-1.08).,,0.67-1.08,,HR 0.85; 0.67-1.08,False,158
For the TEXT+SOFT combined analysis of E+OFS vs T+OFS (n=2346 vs 2344) DFS... continued as significantly improved for E+OFS over T+OFS. 15y DFS was 74.9% vs 71.3% (HR 0.82; 0.73-0.92).,,0.73-0.92,,HR 0.82; 0.73-0.92,True,153
For the TEXT+SOFT combined analysis... BCFI... continued as significantly improved for E+OFS over T+OFS.,,,,,True,156
For the TEXT+SOFT combined analysis... DRFI continued as significantly improved for E+OFS over T+OFS.,,,,,True,155
15y OS was 87.8% vs 87.0% (HR 0.94; 0.80-1.11) respectively.,,0.80-1.11,,HR 0.94; 0.80-1.11,False,159
"The 1-year PFS was 47.6 % (90% CI; 29.2–64.0), achieving the primary endpoint.",,90% CI; 29.2–64.0,,47.6 % (90% CI; 29.2–64.0),True,63
"The most common adverse events were hand and foot syndrome (30.8%, n = 4) followed by cough, decreased absolute neutrophil count, thromboembolic event, and dyspnea which occurred each in 15.4% (n = 2) patients. Only 1 immune related event of dry mouth (sicca) was seen (7.7%). No unexpected adverse events or DLT were seen.",,,,,True,261
"The media RFS was 27.5 months (95% CI: 20.5-NA) in the Len+ TACE group, which was significantly longer than 16.2 months (95% CI: 10.2-NA) in the TACE group (P = 0.04; HR 0.51, 95% CI: 0.27-0.98).",0.04,95% CI: 0.27-0.98,,"HR 0.51, 95% CI: 0.27-0.98",True,281
The DCR was 60% (n = 15),,,,,True,107
No dose-limiting toxicity was reported,,,,,True,93
"The most common (≥ 10%) treatment related adverse events (TRAEs) were grade 1 or 2 vomiting (44.4%), nausea and diarrhea (38.9% each), fatigue (16.7%), ALT increased, blood CPK increased, hyperkalemia and hyperuricemia (11.1% each). No treatment related grade 3 or higher AE or SAE was reported.",,,,,True,94
"Within the 9 pts from phase 1b part (3 in S 200 mg cohort, 6 in S 250 mg cohort), no DLTs occurred thus the RP2D of S was determined as 250mg qd.",,,,,True,123
"In the exploratory analysis, DDR-related mutations seemed predictive for better ORR (85.7% vs 55.6%, P= 0.308)",0.308,,,,False,120
"DDR-related mutations seemed predictive for better... PFS (6-month PFS rate:100% vs 53.3%, log-rank P= 0.519)",0.519,,log-rank,,False,122
"DDR-related mutations seemed predictive for better... OS (6-month OS rate:100% vs 62.5%, log-rank P= 0.116)",0.116,,log-rank,,False,121
"20.0% (90% CI: 3.7-50.7, p = 0.0861)",0.0861,90% CI: 3.7-50.7,,,False,99
"20.0% (90% CI: 5.7-44.0, p = 0.0362)",0.0362,90% CI: 5.7-44.0,,,True,100
"6.7% (90% CI: 0.3-27.9, p = 0.5367)",0.5367,90% CI: 0.3-27.9,,,False,101
Pain scores improved by 18% in the metronomic group compared to 12% in the cisplatin group at week 6 (p = 0.031).,0.031,,,,True,290
Swallowing difficulties decreased by 15% in the metronomic group versus 8% in the cisplatin group (p = 0.042).,0.042,,,,True,292
speech-related challenges showed a 10% improvement in the metronomic group compared to 6% in the cisplatin group (p = 0.049).,0.049,,,,True,291
Fatigue scores improved by 13% in the metronomic group versus 9% in the cisplatin group (p = 0.038).,0.038,,,,True,288
"Emotional well-being also increased significantly, with a 14% improvement in the metronomic group compared to 10% in the cisplatin group (p = 0.045).",0.045,,,,True,287
"While overall HRQoL scores at the study’s end were comparable between groups, metronomic therapy showed superior symptom control and fewer adverse effects, enhancing its tolerability.",,,,,False,289
No major changes were noted in the observed etoposide exposure across Debio 0123 dose levels (200 to 400 mg) after one or three days of co-administration in adult SCLC participants that recurred or progressed after previous platinum treatment. Etoposide PK observed in the study was also in line with literature data (US label Etopophos 2011).,,,,,True,271
Debio 0123 PK was consistent with data previously reported for monotherapy (Abstract #3120 ASCO 2024).,,,,,True,270
"During therapy, a total of 105 SAEs were observed including 74 SAE grade 3, 1 SAE grade 4, and 4 SAE grade 5, with SAEs being ileus, acute pain, cholangiosepsis, infection, small intestinal perforation, or stroke. A Data and Safety Monitoring Board could not find any new and unexpected (S)AEs and recommends continuation of the study.",,,,,True,282
These results provide preliminary support that a decentralized trial assessing neurocognitive outcomes is feasible in patients with CNS malignancy. The completion rates of questionnaires and objective cognitive evaluation are comparable or higher than expected with historic norms.,,,,,True,262
"The median IRC-assessed PFS in anlotinib and bevacizumab group were 11.04 months (95% CI, 9.82-11.17) and 11.04 months (9.69-11.17), respectively, with HR 1.00 (0.84-1.18).",,0.84-1.18,,HR 1.00 (0.84-1.18),False,311
Repeated WTX-212 treatment showed no DLTs or TRAEs ≥3. No patient discontinued treatment due to AEs.,,,NCI-CTCAE v.5.0,,True,65
There were no DLT,,,,,True,96
The confirmed ORR was 33.3%,,,,,True,296
"MPR was documented in 15 (46%, 90% Confidence Interval [CI]: 31%–61%) patients.",,90% CI: 31%–61%,,46% (90% CI: 31%–61%),True,230
All patients achieved complete hematological remission within 31 days of induction.,,,,,True,197
All patients achieved... molecular remission by 28 days of the first consolidation cycle.,,,,,True,198
No patients experienced prolonged neutropenia (> 28 days).,,,,,True,199
No patients experienced... severe mucositis (Grade 3 or 4).,,,,,True,200
No patients experienced... cardiotoxicity.,,,,,True,196
No patients experienced... DIC.,,,,,True,195
MTD was not determined.,,,,,False,89
"MPR was achieved in four (50%) of eight patients. Among six ALK-positive cases, four (67%) patients obtained MPR.",,,,,True,295
"54.7% (95% CI, 39.4 to 67.7) for Afa vs. 57.5% (95% CI, 42.2 to 70.1) for Osi at 3-year survival rate.",,"54.7% (95% CI, 39.4 to 67.7) for Afa vs. 57.5% (95% CI, 42.2 to 70.1) for Osi",,,False,248
"The efficacy of Osi varied significantly dependent on the immunological biomarkers, Th7R (stem cell-like CD4 T cells) and Th2... On the other hand, no immunological biomarkers affected PFS and OS of Afa.",,,,,True,247
"Median progression-free survival (PFS) was 16.7 months (mos) for Afa vs. 14.5 mos for Osi (HR, 1.17; 95% CI, 0.72 to 1.90; P = 0.52).",0.52,"95% CI, 0.72 to 1.90",,"HR, 1.17; 95% CI, 0.72 to 1.90",False,246
"Median OS was 38.8 mos for Afa and not reached for Osi (HR, 1.15; 95% CI, 0.64 to 2.05; P = 0.64)",0.64,"95% CI, 0.64 to 2.05",,"HR, 1.15; 95% CI, 0.64 to 2.05",False,243
"Pts with high Th7R (7.83% or more) had promising PFS (31.0 mos [n = 28] vs. 6.6 mos [n = 20]; HR, 0.38; P = 0.006)",0.006,,,"HR, 0.38",True,245
"OS (not reached vs. 35.5 mos; HR, 0.56; P = 0.18)",0.18,,,"HR, 0.56",False,242
"pts with high Th2 (7.20% or more) had poor PFS (6.6 mos [n = 27] vs. 31.0 mos [n = 21]; HR, 1.78; P = 0.11)",0.11,,,"HR, 1.78",False,244
"OS (35.5 mos vs. not reached; HR, 2.77; P = 0.03)",0.03,,,"HR, 2.77",True,241
"In cohort A, ORR was 8% (6 partial responses [PR], 0 complete responses [CR])",,,,,False,59
EGL-001 was well tolerated with no DLTs reported.,,,,,True,257
no DLTs reported,,,,,True,256
No DLTs or treatment-related AEs (TRAEs) leading to permanent discontinuation were reported. The most common TRAEs were infusion-related reactions and hematologic AEs (Table).,,,modified toxicity probability interval method,,True,221
"The 12-month progression-free survival (PFS) rates for patients with refractory and progressive disease were 79.4% and 35.6%, respectively (P = 0.014).",0.014,,,,True,307
"The 12-month overall survival (OS) rates for patients with refractory and progressive disease were 92.3% and 59.3%, respectively (P = 0.054).",0.054,,,,False,306
"For patients with refractory and progressive disease, those who received sintilimab therapy exhibited a higher 12-month PFS rate compared to those who did not undergo sintilimab treatment (76.9% vs. 44.2%, P = 0.059).",0.059,,,,False,305
median 4.1 mos in ARM A vs 2.4 mos in ARM B,0.15,95% CI: 0.93 – 1.64,Cox proportional hazards model,HR: 1.23 (95% CI: 0.93 – 1.64),False,317
16.0% in ARM A vs 1.9% in ARM B,0.01,95% CI: 0.01 – 0.44,,OR: 0.1 (95% CI: 0.01 – 0.44),True,316
59.4% in ARM A vs 31.8% in ARM B,0.01,95% CI: 0.18 – 0.56,,OR: 0.32 (95% CI: 0.18 – 0.56),True,315
median 2.7 mos in ARM A vs 3.7 mos in ARM B,0.12,95%CI: 0.54 – 1.07,Cox proportional hazards model,HR: 0.76 (95%CI: 0.54 – 1.07),False,321
0% in ARM A vs 17.4% in ARM B,0.01,95% CI: 3.44 - NA,,OR: NA (95% CI: 3.44 - NA),True,320
37.3% in ARM A vs 55.7% in ARM B,0.02,95% CI: 1.11 – 4.27,,OR: 2.17 (95% CI: 1.11 – 4.27),True,319
median 2.7 mos vs 3.9 mos,0.06,95%CI: 0.5 – 1.01,Cox proportional hazards model,HR: 0.71 (95%CI: 0.5 – 1.01),False,318
"The most common AEs were constipation (43.8%) and itching (37.5%), with one reported serious adverse event (SAE) of herpes zoster, and no significant toxicities or treatment-related deaths observed.",,,,,True,260
5/26 (19.2%) had confirmed PR.,,,minimax Simon two-stage design,,True,194
"No dose-limiting toxicities (DLT) were observed in the first six patients receiving PLD (37.5 mg/m², i.v., Day 1, q3w), confirming the RP2D.",,,,,True,34
The MTD was determined to be abemaciclib 150 mg PO BID and niraparib 100 mg PO daily.,,,3+3 dose-escalation algorithm,,True,259
"No DLTs occurred among 3 pts treated at DL1; however, 2 DLTs occurred at DL2, including one hematological DLT (dose delay >7 days due to myelosuppression) and a grade 5 cardiac adverse event (AE).",,,3+3 dose-escalation algorithm,,True,258
"Neoadjuvant treatment improved OS (mOS, Arm A 27.8 vs. 14.6 months Arm B; HR 0.46 [0.22 - 0.96]; p = 0.04)",0.04,0.22 - 0.96,,HR 0.46 [0.22 - 0.96],True,113
Postoperative morbidity rates were similar in both arms (33.3% (A) vs. 32% (B)),,,,,True,114
"no dose-limiting toxicities, neurotoxicity, cytokine release syndrome greater than Grade 2, or graft-versus-host disease were observed.",,,,,True,70
The ORR was 80% in the VEN50 cohort & 81.8% in the VEN400 cohort.,1.0,,,,False,208
CRc rates were comparable between the VEN50 (60%) & VEN400 (63.6%) cohorts.,1.0,,,,False,210
similar MRD negativity rates (30% vs. 36.3%),0.98,,,,False,211
C0 levels of 0.42 µg/mL vs. 1.08 µg/mL (p=0.004),0.004,,,,True,203
Cmax levels of 1.435 µg/mL vs. 3.63 µg/mL (p=0.002),0.002,,,,True,204
"systemic drug exposure in the VEN50 cohort [AUC(0–24):17.88 µg·h/mL vs. 48.05 µg·h/mL, p=0.002]",0.002,,,,True,202
shorter neutropenic phase (17.5 vs. 24 days),0.4,,,,False,207
"febrile neutropenia (60% vs. 72.7%, p=0.501)",0.501,,,,True,206
"culture-positive infections (20% vs. 27.2%, p=0.569)",0.569,,,,True,205
No treatment-related death occurred in either of the group.,,,,,True,209
"The rate of treatment success was 66.7% in the 3-week group and 85.2% in the 6-week group, which did not demonstrate noninferiority in the overall study population (difference, −18.5% percentage points [80% confidence interval {CI}, −29.0% to -7.9%], p = 0.621)",0.621,"80% confidence interval {CI}, −29.0% to -7.9%",,"difference, −18.5% percentage points [80% confidence interval {CI}, −29.0% to -7.9%]",False,45
a predefined exploratory superiority analysis indicated superiority of the 6-week regimen (p = 0.013).,0.013,,,,True,43
"The absolute mean change in the total QOL using the K-BILD score from baseline was 4.78 in the 3-week group and 6.28 in the 6-week group (between-group difference, -1.50 points; 95% CI, −5.91 to 2.91).",,"95% CI, −5.91 to 2.91",,"between-group difference, -1.50 points; 95% CI, −5.91 to 2.91",False,44
"Treatment-related adverse events (TRAEs) occurred in 63.3% of patients. The most common TRAEs (≥10%) included anemia (24.1%), proteinuria (12.7%), increased alanine aminotransferase (11.4%), increased aspartate aminotransferase (11.4%), hyponatremia (10.1%), increased blood lactate dehydrogenase (10.1%), and weight loss (10.2%). Grade 3 TRAEs occurred in 7 patients, including 3 with hypokalemia, 2 with hypertension, 1 with hyponatremia, 1 with proteinuria, and 1 with pulmonary embolism.",,,,,True,72
No dose-limiting toxicities (DLTs) were observed.,,,,,True,71
"30% of pts (9/30) experienced a confirmed response (2 CR, 7 PR); an additional 3 pts (10%) experienced unconfirmed PRs",,,,,True,169
16 pts were alive and progression-free at 6 months. The estimated 6-month PFS was 75.96% (95% CI 53.82-88.51%).,,95% CI 53.82-88.51%,,75.96% (95% CI 53.82-88.51%),True,170
"The most common adverse events were lymphopenia (7 [14.6%]) and decreased appetite (6 [12.5%]). There were no dose-limiting toxicities, cytokine release syndrome, nor related neurotoxicity. One participant was admitted to the hospital for decreased appetite. No long-term toxicities have been noted up to 7.5 months post-infusion.",,,,,True,91
A2B694 was detected post-infusion in the peripheral blood in all patients.,,,,,True,90
A2B694 was detected in an abdominal tumor biopsy from a patient with pancreatic cancer 42 days post-infusion.,,,,,True,92
RD06-03 was well tolerated with no DLT... observed.,,,,,True,201
"The primary end point was met, with rPFS significantly longer with NIRA + AAP (median, not reached [NR]) vs AAP (29.5 mo [95% CI, 25.8-NR]; HR, 0.63 [95% CI, 0.49-0.80], p=0.0001), including in the prespecified BRCA1/2 subgroup (HR, 0.52 [95% CI, 0.37-0.72], p<0.0001).",0.0001,"95% CI, 0.49-0.80","stratified Cox model, stratified log-rank test","HR, 0.63 [95% CI, 0.49-0.80]",True,327
"TSP was significantly improved with NIRA + AAP vs AAP (HR, 0.50 [95% CI, 0.36-0.69], p<0.0001; BRCA1/2: HR, 0.44 [95% CI, 0.29-0.68], p=0.0001).",0.0001,"95% CI, 0.36-0.69","stratified Cox model, stratified log-rank test","HR, 0.50 [95% CI, 0.36-0.69]",True,329
"A trend in OS was seen at this first interim analysis (193/389 events) favoring NIRA + AAP (HR, 0.79 [95% CI, 0.59-1.04], p=0.10; BRCA1/2: HR, 0.75 [95% CI, 0.51-1.11], p=0.15).",0.1,"95% CI, 0.59-1.04","stratified Cox model, stratified log-rank test","HR, 0.79 [95% CI, 0.59-1.04]",False,328
The incidence of irAEs was 31.91% (15/47) in the GQT group and 59.57% (28/47) in the control group. The incidence of irAEs in the GQT group was decreased significantly (P = 0.007).,0.007,,,,True,302
"The ORR was 48.9% (0 CR, 48.9% PR) among response-evaluable patients in the GQT group (n = 45), while it was 36.2% (2.1% CR, 34.0% PR) in the control group (n = 43) (P = 0.211).",0.211,,,,False,304
"The results of 16s rRNA and metabolomics detection of fecal samples showed significant differences in the gut microbiota composition between the T-P and T-A groups (P = 0.019). Compared to C-A patients, Subdoligranulum and Atopobiaceae were increased in T-A patients, while Holdemanella, Atopobium, and Escherichia_Shigella were significantly reduced. Furthermore, prostaglandin A1 was higher, while glyceric acid and deoxyadenosine were lower in the T-A compared with the C-A. And these metabolisms were found to be significantly enriched in glycerolipid metabolism and pentose phosphate pathway.",0.019,,,,True,301
"The median onset time of irAEs in the GQT group was 14.9 weeks, and in the control group was 8.7 weeks (P = 0.807).",0.807,,,,False,303
"Overall, the RCB0/I rate with OC was 52.2% vs. 70.5% with TAC (stratified risk difference = -18.8% (95%CI: -39.6% to 2.0%); p=0.068). In pts with BRCA1/2 PV, RCB0/I rates were comparable: 77.3% (OC) vs. 65.0% (TAC), while in 47 pts with BRCA1/2 wild type (WT), OC was significantly less effective: RCB0/I of 29.2% vs 73.9% in TAC (interaction p=0.008).",0.068,-39.6% to 2.0%,two-sided Cochran Mantel-Haenszel test,stratified risk difference = -18.8% (95%CI: -39.6% to 2.0%),False,164
"The confirmed ORR was 67.6% (95% CI, 49.5-82.6), including 1 patient with a complete response (CR), meeting the primary endpoint.",,"95% CI, 49.5-82.6",Simon's minimax two-stage design,"67.6% (95% CI, 49.5-82.6)",True,124
"At 24 weeks 12.1% (n = 4) experienced > gr 3/4 irAEs, significantly lower than the expected known irAE rate (2-sided p = 0.0007, 95% CI: 12.1%-28.2%).",0.0007,95% CI: 12.1%-28.2%,binomial test,12.1% (95% CI: 12.1%-28.2%),True,250
Circulating IL-6Ra and IL-4 were significantly reduced at Cycle 2 (P < 0.05).,0.05,,Luminex assays,,True,249
"Twelve out of 19 evaluable pts (63%) were still on treatment after 1 year from TS start (median duration 20 months, range 2-29), meeting the primary endpoint.",,,,63%,True,253
"For the BC cohort... DC rate of 37% (90% CI, 24 to 100)... The null DC rate was rejected (p=0.005).",0.005,"90% CI, 24 to 100",,"DC rate of 37% (90% CI, 24 to 100)",True,97
"For the OC cohort... DC rate of 25% (90% CI, 10 to 100)... The null DC rate was not rejected (p=0.29).",0.29,"90% CI, 10 to 100",,"DC rate of 25% (90% CI, 10 to 100)",False,98
There were no significant differences between amulirafusp alfa monotherapy and combination with lenalidomide in terms of PK exposure and ADA incidence rate.,,,,,True,218
There were no significant differences between amulirafusp alfa monotherapy and combination with lenalidomide in terms of PK exposure and ADA incidence rate.,,,,,True,217
"There was no significant difference in... median OS (21.6 vs 37.2 months, p=0.530) and 5-year OS (45.3% vs 41.1%) between PF and PP arm, respectively.",0.53,,,,False,334
"Grade 3/4 hematological (28.6% vs 4.5%, p=0.033)... toxicities were higher in PF arm.",0.033,,,,True,331
"Grade 3/4... gastrointestinal (33.3% vs 4.5%, p=0.015) toxicities were higher in PF arm.",0.015,,,,True,330
QoL (EORTC QLQ-C30 and MSHQ) analysis showed no difference in global health status (p=0.094),0.094,,,,False,333
Patients in PF arm reported more erectile dysfunction-related bother (p=0.018),0.018,,,,True,332
"DC rate of 37% (90% CI, 24 to 100)... The null DC rate was rejected (p=0.005).",0.005,"90% CI, 24 to 100",Simon 2-stage design,"37% (90% CI, 24 to 100)",True,286
"the median PFS was 30.4 months (95% CI: 19.6–NA), meeting the primary endpoint.",,95% CI: 19.6–NA,,median PFS was 30.4 months (95% CI: 19.6–NA),True,14
PAM50 analysis in 75 patients (phase IB/II) showed no significant correlation between intrinsic subtype and efficacy.,,,PAM50 analysis,,False,13
patients with TASOR2 or MST1R mutation demonstrated a significantly lower pCR rate (both P=0.041).,0.041,,,,True,173
CCND1 amplification showed a non-significant negative trend with the pCR rate (P=0.051).,0.051,,,,False,172
"In the 21 safety evaluable patients, only 1 DLT of Grade 3 increased alanine aminotransferase, in the context of multiple viral infections, was reported. The DLT resolved after treatment interruption and Alectinib was restarted at a reduced dose level, and then tolerated well. Eighteen patients (86%) experienced at least one Adverse Event (AE) reported as related to Alectinib, the majority being of Grade 1 and 2 severity. Grade ≥ 3 AEs related to alectinib were reported for 5 patients (23.8%) and there were 2 patients with serious AEs related to Alectinib. There were no new safety signals detected.",,,,,True,3
"Patients were recruited to Part 1 to confirm the recommended phase 2 dose (RP2D)... only 1 DLT of Grade 3 increased alanine aminotransferase... was reported. The DLT resolved after treatment interruption and Alectinib was restarted at a reduced dose level, and then tolerated well.",,,,,True,2
Investigator reported Best Overall Response rate in 16 patients was 87.5%; (14 PRs) and 2 patients were reported to have stable disease.,,,,,True,1
"In the 11 pts monitored via next-generation sequencing (NGS), ctDNA clearance post-treatment correlated significantly with improved PFS (median PFS: NR vs. 17.8 months, P=0.015).",0.015,,,,True,240
"Median EFS was 5.1 mos (95% CI 3.1, 6.3) for IFOS and 3.5 mos (95% CI 2.5, 6.1) for CE. Given the observed data the posterior probabilities that EFS... were better after IFOS than after CE (ie Pr[true hazard ratio > 1 | data]) were 87%...",,"95% CI 3.1, 6.3 (for IFOS); 95% CI 2.5, 6.1 (for CE)",probability-based Bayesian approach,,False,5
"Median OS was 14.4 mos (95% CI 11.5, 20.7) for IFOS and 19.0 mos (95% CI 11.2, 24.6) for CE. Given the observed data the posterior probabilities that... OS were better after IFOS than after CE... were... 55%...",,"95% CI 11.5, 20.7 (for IFOS); 95% CI 11.2, 24.6 (for CE)",probability-based Bayesian approach,,False,6
No treatment-related serious or grade > 3 adverse events were reported.,,,,,True,76
"the study reached the significantly improved BICR-assessed ORR with MRG003 compared to chemotherapy (30.2% vs. 11.5%, difference: 18.7%, 95%CI: 7.0%, 30.5%, P=0.0025).",0.0025,"95%CI: 7.0%, 30.5%",,"difference: 18.7%, 95%CI: 7.0%, 30.5%",True,343
"PFS was significantly improved in the MRG003 arm (HR=0.63, 95%CI: 0.43, 0.91, P=0.0146). Median PFS (95%CI) by BICR were 5.8m (4.2, 6.2) vs. 2.8m (2.0, 5.5).",0.0146,"95%CI: 0.43, 0.91",,"HR=0.63, 95%CI: 0.43, 0.91",True,346
"As of 30 December 2024, the updated mOS (95%CI) were 17.1m (11.4, NE) vs. 12.0m (9.7, 15.4) of two arms (HR=0.73, 95%CI: 0.48, 1.12).",,"95%CI: 0.48, 1.12",,"HR=0.73, 95%CI: 0.48, 1.12",False,344
"By supplementary analysis excluding the impact of crossover treatment, the HR of OS was 0.59 (95%CI: 0.37, 0.93).",,"95%CI: 0.37, 0.93",,"HR of OS was 0.59 (95%CI: 0.37, 0.93)",True,345
"in the intent-to-treat population the hazard ratio (HR) for OS adjusted for stratification factors after concTMZ was 0.906 (95%CI 0.760, 1.082; p=0.28)",0.28,"95%CI 0.760, 1.082",,"HR...0.906 (95%CI 0.760, 1.082)",False,58
"after adjTMZ 0.647 (95%CI 0.541, 0.773; p <0.0001)",0.0001,"95%CI 0.541, 0.773",,"HR...0.647 (95%CI 0.541, 0.773)",True,57
For patients with IDHmt tumors the HR for concTMZ was 0.81 (95% CI 0.63-1.04; p=0.09),0.09,95% CI 0.63-1.04,,HR for concTMZ was 0.81 (95% CI 0.63-1.04),False,56
"for adjTMZ 0.54 (95% CI 0.42-0.69,p < 0.0001)",0.0001,95% CI 0.42-0.69,,HR...for adjTMZ 0.54 (95% CI 0.42-0.69),True,55
No benefit was observed of concTMZ in IDHmt glioma patients that also received adjTMZ (HR 0.92 95% CI 0.63-1.36; p=0.69),0.69,95% CI 0.63-1.36,,HR 0.92 95% CI 0.63-1.36,False,53
the median OS in patients treated with adjTMZ was 12.5 years (95% CI 9.4-15.0; p<0.0001),0.0001,95% CI 9.4-15.0,,,True,54
"patients with ≥30% intense and complete CEA staining in tumor cells and no brain metastases showed better PFS (72.7% vs. 25.0%, p=0.03)",0.03,,,,True,237
"patients with ≥30% intense and complete CEA staining in tumor cells and no brain metastases showed better... OS (90.9% vs. 0%, p=0.003)",0.003,,,,True,236
"The CCRT+T group had higher... objective response rates (ORR) compared to the CCRT group, with... ORR rates of 100% versus 84.6% (p = 0.046).",0.046,,,,True,82
There was no significant difference in the incidence of acute adverse reactions between the two groups (P > 0.05).,,,,,True,83
"no statistical difference was observed in the... PFS (p = 0.716) between the two groups, as shown by the Kaplan-Meier survival curves.",0.716,,Kaplan-Meier survival curves,,False,78
"no statistical difference was observed in the OS (p = 0.414)... between the two groups, as shown by the Kaplan-Meier survival curves.",0.414,,Kaplan-Meier survival curves,,False,77
"The CCRT+T group had higher complete response (CR)... rates compared to the CCRT group, with CR rates of 44.4% versus 19.2% (p = 0.035)",0.035,,,,True,80
the double positive T lymphocyte subset percent (p = 0.025)... showed significant increases.,0.025,,,,True,81
absolute CD4+T lymphocyte count (p = 0.047) showed significant increases.,0.047,,,,True,79
"The median PFS evaluated by IRC was 9.89 months (95% CI 9.10, 11.56) in the ALTN group, 5.85 months (95% CI 3.58, 7.69) in the PLB group [HR 0.59 (95% CI 0.42,0.85), p= 0.0043].",0.0043,"95% CI 0.42,0.85",log-rank tests,"HR 0.59 (95% CI 0.42,0.85)",True,309
"The ORR evaluated by IRC was 16.88% (95% CI 9.31,27.14) in the ALTN group, 5.26% (95% CI 1.45,12.93) in the PLB group [p= 0.0220].",0.022,"95% CI 9.31,27.14",exact binomial methods,,True,310
"30 patients (83%) had surgery after neoadjuvant DTP, achieving R0/R1 resection in 29/30 (97%).",,,,,True,178
"Mean surgical morbidity score (0-4 scale, 4=unresectable) improved from 3.3 to 1.6 after DTP (p<0.01).",0.01,"(-2.1, -1.3)",,"Surgical morbidity score change, mean (95% CI) -1.7 (-2.1, -1.3)",True,179
"Complete pathologic responders had better 2-year OS than those with residual ATC (69% vs. 22%, p=0.02).",0.02,,,,True,177
"Arm A: 44.1% (95% CI 27.2, 62.1); Arm B: 34.3% (95% CI 19.1, 52.2); Arm C: 2.9% (95% CI 0.07, 15.3). The abstract states: ""Arm A and B had comparable ORR... all statistically superior to Arm C.""",,"Arm A: (27.2, 62.1); Arm B: (19.1, 52.2); Arm C: (0.07, 15.3)",Cochran-Mantel-Haenszel test,"Rate difference (Arm A vs C): 41.2 (23.7, 58.6); Rate difference (Arm B vs C): 31.1 (14.6, 47.5)",True,323
"Arm A: 82.4% (95% CI 65.5, 93.2); Arm B: 85.7% (95% CI 69.7, 95.2); Arm C: 61.8% (95% CI 43.6, 77.8). The abstract states: ""Arm A and B had comparable... DCR... all statistically superior to Arm C.""",,"Arm A: (65.5, 93.2); Arm B: (69.7, 95.2); Arm C: (43.6, 77.8)",Cochran-Mantel-Haenszel test,"Rate difference (Arm A vs C): 20.6 (0.06, 41.1); Rate difference (Arm B vs C): 23.9 (3.85, 43.9)",True,322
"Arm A: 5.7 mo (95%CI 3.75, NR); Arm B: 7.4 mo (95%CI 3.91, NR); Arm C: 2.9 mo (95%CI 2.14, 3.71). The abstract states: ""Arm A and B had comparable... PFS, all statistically superior to Arm C.""",0.001,"Arm A: (3.75, NR); Arm B: (3.91, NR); Arm C: (2.14, 3.71)",stratified log - rank test,"mPFS Arm A: 5.7 (3.75, NR); mPFS Arm B: 7.4 (3.91, NR)",True,324
DL +1 (tala 0.75 mg QD + taz 800 mg BID) was selected as the RP2D.,,,3+3 design,,True,150
"Grade ≥3 treatment-related AEs were reported in 59% of pts (16/27), including thrombocytopenia (8/27, 29.6%), anemia (8/27, 29.6%), fatigue (4/27, 14.8%), neutropenia (3/27, 11.1%), lymphopenia (1/27, 3.7%), and hyperglycemia (1/27, 3.7%). 14 of 27 pts (51.8%) required dose reduction. The combination was associated with expected myelosuppression but otherwise acceptable safety profile.",,,,,True,151
"During RT, ‘no nausea’ ... complain in placebo & experimental arms were 16.3 & 85.8% (p= <0.001)",0.001,,Pearson chi-square test,,True,40
"During RT, ... ‘no vomiting’ complain in placebo & experimental arms were ... 74.5% & 95.9% (p= <0.001)",0.001,,Pearson chi-square test,,True,41
Rescue therapy during RT required in 7.8% placebo &1.4% in experimental arm (p=0.008).,0.008,,Pearson chi-square test,,True,42
Total number of vomiting episodes >15 times during RT in placebo & experimental arm were 9.2% & 2% (p=0.002).,0.002,,Pearson chi-square test,,True,39
Mean anxiety score before & after RT in placebo was 13.2 (+/-2.5) &14.5 (+/-2.4) (p<0.001); in experimental arm 13.4 (+/-2.3) & 11.1 (+/-2.2) (p<0.001),0.001,,independent t-test,,True,36
Mean depression score before & after RT in placebo & experimental arm were 11.9 (+/-1.6) & 13.7 (+/-1.8) (p<0.001); 11.9 (+/-1.6) & 9.7 (+/-1.6) (p<0.001),0.001,,independent t-test,,True,37
The olanzapine group had more sleep hours/day (8.4 ±1.7 hours vs. 5.29 ±1.13 hours; p<0.001).,0.001,,independent t-test,,True,38
Mean EORTC GHS QOL score at RT completion was 61.6 (+/- 8.6) in placebo arm and 62.9 (+/-9.2) in experimental arm (p=0.235).,0.235,,independent t-test,,False,35
achieved in 92/109 (84%) patients receiving ROMI vs 20/56 (36%) receiving PBO (odds ratio 10.2; 95% CI 4.6-22.5; P<0.001),0.001,95% CI 4.6-22.5,,odds ratio 10.2; 95% CI 4.6-22.5,True,47
"Median (range) Plt nadirs were ROMI 87 (14–167)×10^9/L, PBO 58 (22–95)×10^9/L; P=0.005.",0.005,,,,True,46
"median (95% CI) time to first Plt response was ROMI 1.1 (not estimable) weeks, PBO 2.1 (1.1-3.0) weeks; P<0.001.",0.001,"ROMI: (not estimable), PBO: (1.1-3.0)",,,True,48
"Median DFS was not reached (NR) vs 68.3 mo, respectively (HR 0.71, 95% CI 0.59−0.86); estimated DFS rate at 5 yrs was 60.9% vs 52.2%.",,95% CI 0.59−0.86,,"HR 0.71, 95% CI 0.59−0.86",True,130
"Median OS was NR in both arms (HR 0.66, 95% CI 0.48−0.90); estimated OS rate at 5 yrs was 87.7% vs 82.3%, respectively.",,95% CI 0.48−0.90,,"HR 0.66, 95% CI 0.48−0.90",True,131
No new serious treatment-related AEs have been reported for ≥3 years.,,,,,True,132
"One patient in dose level 2 (25x10^6 cells) experienced a DLT (grade 3 hypertension). No additional DLTs were observed in this dose level after expansion to 6 patients, and the recommended phase 2 dose was established at 25x10^6 cells. Toxicity otherwise has been primarily related to tumor inflammation-associated neurotoxicity (TIAN), observed after 29 of 36 infusions (81%), and managed acutely with anakinra and dexamethasone.",,,,,True,61
"Eleven patients were enrolled, underwent apheresis, and had B7H3-CART successfully manufactured.",,,,,True,60
The cCR-rate was 38.7% (N = 12; 95%CI: 21.8-57.8),,95%CI: 21.8-57.8,,38.7% (N = 12; 95%CI: 21.8-57.8),True,136
"luminal tumors showing higher ypT0 rates vs non-luminal (73 vs 25%, p = 0.04)",0.04,,,,True,137
Higher stromal signature (> median) was associated with non-ypT0 response (p = 0.004),0.004,,,,True,135
neither Trop2 (p = 0.15) ... gene expression were associated with ypT0 response.,0.15,,,,False,134
neither ... TOP1 (p = 0.79) gene expression were associated with ypT0 response.,0.79,,,,False,133
The number of ctDNA mutations (P < 0.001)... all decreased with therapeutic response.,0.001,,,,True,274
mutation abundance (P < 0.001)... all decreased with therapeutic response.,0.001,,,,True,272
mutation level (P < 0.001) all decreased with therapeutic response.,0.001,,,,True,273
"With a median follow-up of 117.6 months, the 10-year DFS rate was 83.7% in the TAM + OFS group compared to 75.9% in the TAM-only group (hazard ratio [HR], 0.68; 95% CI, 0.53-0.87).",,"95% CI, 0.53-0.87",,"HR, 0.68; 95% CI, 0.53-0.87",True,162
"there were no significant differences in 10-year OS: 94.6% in the TAM + OFS vs. 93.2% in the TAM-only group (HR, 0.79; 95% CI, 0.50-1.27).",,"95% CI, 0.50-1.27",,"HR, 0.79; 95% CI, 0.50-1.27",False,163
"Among patients with a high composite risk score (4–5, n = 282, 36.3% of the HER2-negative cohort), the 10-year BCFI was significantly improved with OFS: 76.6% in the TAM + OFS group vs. 65.7% in the TAM-only group (HR, 0.62; 95% CI, 0.40–0.98).",,"95% CI, 0.40–0.98",Cox regression model,"HR, 0.62; 95% CI, 0.40–0.98",True,161
"With 9 years median follow-up, OS was improved with NIVO+IPI vs SUN in ITT (HR 0.71) and I/P (HR 0.69) pts. The probability of OS at 108 months was 31% vs 20% in ITT pts and 30% vs 19% in I/P pts, respectively. In pts with FAV risk, the HR for OS improved from 1.45 at first report (Motzer NEJM 2018) to 0.80 at 9 years, showing a delayed benefit with NIVO+IPI vs SUN. OS probabilities at 108 months were 35% vs 22% in FAV pts, respectively. mOS (95% CI), mo: I/P NIVO+IPI 47 (35–56) vs SUN 26 (22–33). 108-mo OS probabilities (95% CI), %: I/P NIVO+IPI 30 (26–35) vs SUN 19 (15–23).",,"mOS (95% CI), mo: 47 (35–56) vs 26 (22–33); 108-mo OS probabilities (95% CI), %: 30 (26–35) vs 19 (15–23)",,HR 0.69,True,128
"With 9 years median follow-up, OS was improved with NIVO+IPI vs SUN in ITT (HR 0.71)...pts. The probability of OS at 108 months was 31% vs 20% in ITT pts. mOS (95% CI), mo: ITT NIVO+IPI 53 (46–64) vs SUN 38 (32–44). 108-mo OS probabilities (95% CI), %: ITT NIVO+IPI 31 (27–35) vs SUN 20 (16–23).",,"mOS (95% CI), mo: 53 (46–64) vs 38 (32–44); 108-mo OS probabilities (95% CI), %: 31 (27–35) vs 20 (16–23)",,HR 0.71,True,129
"ORR per IRRC (95% CI); CR, %: I/P NIVO+IPI 42 (38–47); 12 vs SUN 27 (23–32); 3.",,42 (38–47) vs 27 (23–32),,,True,127
No new treatment-related deaths occurred in either arm. No new safety signals emerged.,,,,,True,125
"The probability of remaining in response through 96 months with NIVO+IPI vs SUN was 48% vs 19% in ITT pts, 50% vs 23% in I/P pts, and 36% vs not available (NA) in FAV pts. mDOR (95% CI), mo: ITT 76 (59–NE) vs 25 (20–33); I/P 83 (54–NE) vs 20 (16–26); FAV 61 (23–NE) vs 33 (25–51).",,"mDOR (95% CI), mo: ITT 76 (59–NE) vs 25 (20–33); I/P 83 (54–NE) vs 20 (16–26); FAV 61 (23–NE) vs 33 (25–51)",,,True,126
"the 2-year OS of whole cohort was 67.2%, and 73.8% vs 51.2% (P = 0.019) in reRT group vs no reRT group.",0.019,,,,True,186
"The 2-year progression-free survival (PFS) of whole cohort was 47.9%, and 61.0% vs 24.3% (P < 0.0001) in reRT group vs no reRT group.",0.0001,,,,True,187
The CR rate after neoadjuvant treatment was 36.0% (27 of 75) in the toripalimab arm and 13.3% (10 of 75) in the standard arm (P= 0.001).,0.001,,,,True,188
The overall response rate (ORR) after neoadjuvant treatment was 94.7% (71 of 75) in the toripalimab arm and 85.3% (64 of 75) in the standard arm (P= 0.042).,0.042,,,,True,191
Grade 3-4 acute treatment-related adverse events (trAEs) occurred in 50 (66.7%) patients in the toripalimab arm and46 (61.3%) patients in the standard arm (P= 0.496).,0.496,,,,True,189
immune-related AEs (irAEs) reported in 5 (6.7%) patients in the toripalimab arm and none (0.0%) in the standard arm (P= 0.058).,0.058,,,,True,190
"One DLT of Grade 3 enterocolitis was observed at dose level 50 mg/m². The most common Grade 3/4 AEs occurring in > 30% of patients, during the first 3 treatment cycles were: febrile neutropenia 13 (59.1%), neutropenia 13 (59.1%); leukopenia 12 (54.5%); anaemia 10 (45.5%), and lymphopenia 7 (31.8%).",,,,,True,12
The HTD and RP2D of irinotecan in combination with IVA were established as 50 mg/m²/day.,,,,,True,10
The HTD and RP2D of irinotecan in combination with IVA were established as 50 mg/m²/day.,,,,,True,11
"The iTNBC cohort showed significantly longer OS (25.8 vs. 18 months, HR = 0.50, 95%CI: 0.26-0.98, p = 0.043) compared to cTNBC.",0.043,95%CI: 0.26-0.98,,"HR = 0.50, 95%CI: 0.26-0.98",True,26
"With the caveat of comparing sequential cohorts, the iTNBC cohort showed a trend for higher ORR (47% vs. 23%, p= 0.08) ... compared to cTNBC. Confirmed ORR (CR+PR) for cTNBC was 7/30 (23%) and for iTNBC was 9/19 (47%).",0.08,,,,False,25
"The iTNBC cohort showed... longer median PFS (8.4 vs. 5.5 months, HR = 0.68, 95%CI: 0.37-1.24)... compared to cTNBC.",,95%CI: 0.37-1.24,,"HR = 0.68, 95%CI: 0.37-1.24",False,28
"PD-L1 expression, while not different at baseline, remained unchanged in cTNBC but increased significantly in iTNBC (p< 0.02), possibly reflecting pembrolizumab-driven immune modulation.",0.02,,,,True,27
"Across both cohorts higher LNR was associated with improved OS (R= 0.37, p= 0.0075)",0.0075,,,R= 0.37,True,23
"conversely, higher MLR was associated with poorer OS (R= -0.46, p= 0.00087).",0.00087,,,R= -0.46,True,24
"Regarding the quality of life analysis, in the overall assessment date were not statistically significant...",,,paired t-test or signed-rank test,,False,51
"difference was observed in the levels of insomnia (p-value 0.01) ... between patients in the CBD and placebo groups, with results favoring the CBD group.",0.01,,paired t-test or signed-rank test,,True,50
"difference was observed in the levels of ... dyspnea (p-value 0.02) between patients in the CBD and placebo groups, with results favoring the CBD group.",0.02,,paired t-test or signed-rank test,,True,49
"3 of the first 19 recruited patients achieved an objective response (15.8%, 95% confidence interval (CI) 3.4 - 39.6; 3 partial and no complete responses)",,95% confidence interval (CI) 3.4 - 39.6,Simon 2 stage statistical design,"15.8%, 95% confidence interval (CI) 3.4 - 39.6",False,145
Adverse events were predominantly disease related. Atezolizumab was well tolerated with no new safety signals observed relating to this treatment.,,,,,True,146
"In the mITT analysis, the pCR rate was 26.8% vs. 15.4% vs. 9.8% among the 3 groups, respectively. For mFOLFOXIRI+AK104 (A) vs mFOLFOX6 (C), the result was 11 (26.83%) vs 4 (9.76%).",0.046,,,,True,111
"The MPR rate was 68.3%, 48.7% and 43.9%, respectively. For mFOLFOXIRI+AK104 (A) vs mFOLFOX6 (C), the result was 28 (68.3%) vs 18 (43.9%).",0.026,,,,True,110
"The downstaging (ypStage 0 to 1) was 65.9%, 46.2% and 41.5%, respectively. For mFOLFOXIRI+AK104 (A) vs mFOLFOX6 (C), the result was 27 (65.9%) vs 17 (41.5%).",0.026,,,,True,109
"the pCR rates were 30.6%, 17.1%, and 10.8%, respectively. For mFOLFOXIRI+AK104 (A) vs mFOLFOX6 (C), the result was 11 (30.6%) vs 4 (10.8%).",0.036,,,,True,112
"There was no dose-limiting toxicity (DLT), treatment-emergent ICU transfer, or treatment-related mortality (TRM). Eight pts had G≥3 nonhematologic TEAEs (events in > 1 pt: hyponatremia, hypokalemia [n = 2 each]). One pt reported 2 OBX-115–related serious AEs, including 1 CRS event (G2) without IL6 elevation (IL6 < 100 pg/mL).",,,,,True,251
ACZ redosing is well-tolerated.,,,,,True,252
"The RP2D was determined as Fluzoparib 0.1g bid. plus Dalpiciclib 0.15g qd, d1-d21, q4w.",,,i3+3 dose escalation design,,True,33
"The most common treatment-emergent AEs (TEAEs, ≥20%) were leukopenia, neutropenia, etc. 3 pts (25%) had grade ≥3 TRAEs and no drug-related AEs led to death. In Cohort 4, 1 pt experienced dose-limiting toxicity (DLT) of grade 3 thrombocytopenia, and the other 1 pt experienced DLT of severe stun.",,,,,True,32
"Median PFS by Blinded Independent Central Review (BICR) met the primary endpoint at 3.42 months (95% CI: 2.60, 6.83) for (C) and 1.41 months (95% CI: 1.35, 4.86) for (P) with a p-value of 0.0265 and a HR of 0.536 (95% CI: 0.307, 0.936).",0.0265,"95% CI: 0.307, 0.936",Log Rank test,"HR of 0.536 (95% CI: 0.307, 0.936)",True,31
"Median PFS for patients stratified at ≤ 3 prior lines was 4.86 months (95% CI: 2.04, 8.94) for (C) and 1.41 months (95% CI: 1.31, 4.86) for (P) with a p-value of 0.0046 and a HR of 0.386 (95% CI: 0.196, 0.760).",0.0046,"95% CI: 0.196, 0.760",,"HR of 0.386 (95% CI: 0.196, 0.760)",True,30
The trial met its primary endpoint with an MRD-neg rate after consolidation of 73.2% in the MRD-analysis population (153/209; 10 not assessable).,,,,,True,220
"Reaching and remaining in MRD-neg state led to a significant PFS benefit (hr 0.16 [0.08;0.32], time-dependent Cox regression).",,[0.08;0.32],time-dependent Cox regression,hr 0.16 [0.08;0.32],True,219
"Overall, 73 treatment-emergent adverse events (TEAEs) were reported in 5 patients (n = 73; N = 5). Most TEAEs were NCI-CTCAE Grade 1 (n = 38; N = 5) or Grade 2 (n = 26; N = 5). The most common Grade 1 and Grade 2 TEAEs were diarrhea (n = 4; N = 3) and hypokalemia (n = 3; N = 3), respectively. Of the Grade 3 TEAEs (n = 9; N = 4), the most reported were platelet count decreased (n = 3; N = 1). Of all TEAEs, 31 events were related to both PBP1510 and gemcitabine (n = 31; N = 4). The most reported TEAEs related to PBP1510 only and to gemcitabine only were diarrhea (n = 2; N = 1) and platelet count decreased (n = 8; N = 1), respectively. Most treatment-related TEAEs were Grade 1 (n = 14; N = 3) or Grade 2 (n = 13; N = 4). Clinically significant laboratory abnormalities were observed for hematology (n = 7; N = 5; Grade 1-3) and blood chemistry (n = 4; N = 2; Grade 1-2). No DLTs and no serious TEAEs were reported.",,,,,True,284
Interim safety data from the dose-escalation of PBP1510 demonstrate acceptable tolerability at up to 3 mg/kg in combination with gemcitabine in metastatic pancreatic adenocarcinoma patients who had failed previous treatment(s).,,,,,True,285
No DLTs and no serious TEAEs were reported.,,,,,True,283
"TEAEs occurred in 12 (92.3%) patients, and ≥Grade 3 TEAEs occurred in 6(46.2%) patients. The most common≥Grade 3 TEAEs is hematological AEs, including lymphopenia (8.3%), neutropenia (8.3%) and thrombocytopenia (8.3%). Two patients (16.7%) reported serious TEAEs, including edema and cardiac failure reported by the SS patient which was assessed as not related to ICP-B05, and thrombocytopenia and anemia reported by a MF patient. There was no fatal TEAE reported.",,,,,True,67
"PD analysis demontrated significant depletion of CCR8-expressing cells in CTCL skin lesions. Significant reduction of CCR8+ malignant T cells (-80%) and CCR8+ regulatory T cells (Treg, -68%) were observed at C3D1 compared with baseline in the skin lesion. Similar PD effects were observed in the peripheral blood as well with an average decrease of 91% in CCR8+ malignant T cells and 16% in Treg at C3D1 when compared with baseline.",,,,,True,66
The Part 2 dose of Adrixetinib is confirmed at 120 mg.,,,mTPI design,,True,73
"there were no treatment discontinuations due to the treatment-related AEs (TRAEs). Most common TRAEs ≥10% were AST increase (51.7%), ALT increase (41.3%), CPK increase (37.8%) and LDH increase (34.5%). One patient dosed at 120 mg experienced 1 DLT (G3 skin rash and G3 diarrhea).",,,,,True,75
"Overall response assessment (RECIST 1.1) included 1 confirmed complete response (CR) in a patient with metastatic gastric cancer (GC) and 6 patients with stable disease (SD) across multiple tumor types. Among 6 SD patients, 1 GC and 1 hepatocellular cancer (HCC) patient continued treatment for ≥24 weeks.",,,RECIST 1.1,,True,74
